NitiNotes Overview
Nitinotes is a clinical-stage company developing a revolutionary treatment for obesity. Its flagship product, the EndoZip, simplifies and speeds up endoscopic gastroplasty procedures, offering a widely available, minimally invasive, and effective solution for over 700 million patients with obesity class I & II for whom traditional bariatric surgery is not an option. EndoZip is an automated and operator-independent, minimally invasive robotic suturing system, for safe and easy delivery of effective restrictive sutures to the stomach wall. Nitinotes is conducting a series of pilot studies in various sites around the world aimed at fortifying both its clinical and economic cases.
Cumulative Funding Raised Over Time ($)
Latest News
Nitinotes announces closing $9.3M SAFE round
growth-positive
/PRNewswire/ -- Nitinotes, developers of EndoZip™, a fully automated endoscopic suturing system, proudly announces the publication of their pivotal study,...
Nitinotes, developers of the EndoZip™ endoscopic suturing system, announced the publication of their pivotal study in the journal GIE: Gastrointestinal Endoscopy. The study demonstrated the effectiveness of EndoZip™ in achieving significant weight loss and improving metabolic health indicators over 12 months. The procedure was successful in all patients, highlighting its safety and feasibility. CEO Lloyd Diamond emphasized the studys validation of EndoZip™ technology and its potential to enhance accessibility to obesity treatments. This publication marks a significant step in advancing minimally invasive obesity management solutions.
growth-positive
Nitinotes announces closing of an internal $7.1M series A1 funding - TechWald Holding S.p.A.
Nitinotes Surgical has announced the closing of an internal $7.1M series A1 funding round, bringing the total funds raised by the company to $13.5M. The funding will be used to finalize the development of the Endozip automated suturing system and execute a multi-center pilot study in the EU.
Investment
Amid obesity, Israeli startup develops Endozip device to stitch up stomach bulge
growth-positive
Amid obesity, Israeli startup develops Endozip device to stitch up stomach bulge
Israeli company Nitinotes is developing a minimally invasive and fully automated gastrointestinal suturing system called Endozip to reduce stomach volume in patients with class one or class two obesity. The device will be inserted and removed through the mouth and esophagus, requiring minimal anesthesia and a short hospital stay. Nitinotes recently conducted a successful trial with 13 patients, and plans to conduct larger studies in Europe and the US. The company has raised a total of NIS 3.5 million ($673,000) in funding from various investors. Nitinotes aims to offer a safer, more effective, and competitively priced alternative to existing surgical solutions for obesity.
Customers
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $32.9M |
| Last funding | $9.3M |
| Stage | B |
| Rounds | 4 |
| Investors | 5 |
Team Members
4
Employees: 11-50
Web & Social Links
| Website | nitinotesurgical.com |
Locations
HaEshel Street 5, Caesarea, Israel
Photos & Videos
1 item(s)
